Moreover, our data reveal that the use of inhibitors of the METTL3/METTL14 complex may represent an effective therapy for killing CML cells that evade tyrosine kinase inhibition. Here, METTL3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.